U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H22N2OS.ClH
Molecular Weight 338.895
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of NETICONAZOLE HYDROCHLORIDE

SMILES

Cl.CCCCCOC1=C(C=CC=C1)C(=C/SC)\N2C=CN=C2

InChI

InChIKey=HAHMABKERDVYCH-ZUQRMPMESA-N
InChI=1S/C17H22N2OS.ClH/c1-3-4-7-12-20-17-9-6-5-8-15(17)16(13-21-2)19-11-10-18-14-19;/h5-6,8-11,13-14H,3-4,7,12H2,1-2H3;1H/b16-13+;

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C17H22N2OS
Molecular Weight 302.434
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Sources: Ludwig Zirngibl. Antifungal Azoles: A Comprehensive Survey of their Structures and Properties. 1998 Wiley-VCH Verlag GmbH ISBN: 3-527-29487-2 DOI: 10.1002/3527602682 p.83

Neticonazole is an antifungal drug. It is especially active against Candida glabrata, Trichophyton, Microsporum, Aspergillus and Fonsecaea spp. Clinical experience demonstrated neticonazole as a safe and effective treatment of mycoses like trichophytosis, candidiasis, and different types of tinea.

Originator

SS Pharmaceutical
3
Sources: Ludwig Zirngibl. Antifungal Azoles: A Comprehensive Survey of their Structures and Properties. 1998 Wiley-VCH Verlag GmbH ISBN: 3-527-29487-2 DOI: 10.1002/3527602682 p.83

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
Atolant

Approved Use

Neticonazole is used as a topical ointment in Japan under the tradename Atolant for treatment of mycoses.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.9 ng/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/4/650034_2655711M1039_4_111_1F.pdf#page=26
100 mg single, topical
dose: 100 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
NETICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
63.3 ng × h/mL
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/4/650034_2655711M1039_4_111_1F.pdf#page=26
100 mg single, topical
dose: 100 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
NETICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.63 h
OTHER GOV'T
https://www.info.pmda.go.jp/go/interview/4/650034_2655711M1039_4_111_1F.pdf#page=26
100 mg single, topical
dose: 100 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
NETICONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1 % 1 times / day multiple, topical
Recommended
Dose: 1 %, 1 times / day
Route: topical
Route: multiple
Dose: 1 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8734665/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/8734665/
Other AEs: Pruritus, Contact dermatitis...
Other AEs:
Pruritus (0.8%)
Contact dermatitis (0.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8734665/
1 % 1 times / day multiple, topical
Recommended
Dose: 1 %, 1 times / day
Route: topical
Route: multiple
Dose: 1 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9330830/
unknown, ADULT
Health Status: unknown
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/9330830/
Other AEs: contact dermatiti...
Other AEs:
contact dermatiti
Sources:
https://pubmed.ncbi.nlm.nih.gov/9330830/
1 % 1 times / day multiple, topical
Recommended
Dose: 1 %, 1 times / day
Route: topical
Route: multiple
Dose: 1 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9062749/
unknown, ADULT
Health Status: unknown
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/9062749/
Other AEs: Contact dematitis...
Other AEs:
Contact dematitis
Sources:
https://pubmed.ncbi.nlm.nih.gov/9062749/
AEs

AEs

AESignificanceDosePopulation
Contact dermatitis 0.8%
1 % 1 times / day multiple, topical
Recommended
Dose: 1 %, 1 times / day
Route: topical
Route: multiple
Dose: 1 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8734665/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/8734665/
Pruritus 0.8%
1 % 1 times / day multiple, topical
Recommended
Dose: 1 %, 1 times / day
Route: topical
Route: multiple
Dose: 1 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8734665/
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/8734665/
contact dermatiti
1 % 1 times / day multiple, topical
Recommended
Dose: 1 %, 1 times / day
Route: topical
Route: multiple
Dose: 1 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9330830/
unknown, ADULT
Health Status: unknown
Age Group: ADULT
Sex: F
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/9330830/
Contact dematitis
1 % 1 times / day multiple, topical
Recommended
Dose: 1 %, 1 times / day
Route: topical
Route: multiple
Dose: 1 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9062749/
unknown, ADULT
Health Status: unknown
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/9062749/
PubMed

PubMed

TitleDatePubMed
Effects of antifungal drugs on proliferation signals in Candida albicans.
2006-05
Comparison of in vitro antifungal activities of topical antimycotics launched in 1990s in Japan.
2001-08
[Therapeutic efficacies of neticonazole (SS717) cream and solution in experimental cutaneous Candida albicans infection of guinea pigs].
1993-10
Patents

Patents

EP1568366A1
2
JP2004083439A
2
JP2005170913A
2
JPH0820527A
3
US20050186161
2

Sample Use Guides

In Vivo Use Guide
1% cream applied once a day on the affected and surrounding area.
Route of Administration: Topical
In Vitro Use Guide
antifungal activity of Neticonazole at 1 ug/ml
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:27:17 GMT 2025
Edited
by admin
on Mon Mar 31 18:27:17 GMT 2025
Record UNII
PKF582ZH6P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NETICONAZOLE HYDROCHLORIDE
JAN   MART.   MI   WHO-DD  
Common Name English
SS 717
Preferred Name English
SS-717
Code English
NETICONAZOLE HYDROCHLORIDE [MART.]
Common Name English
NETICONAZOLE HYDROCHLORIDE [JAN]
Common Name English
Neticonazole hydrochloride [WHO-DD]
Common Name English
1-((E)-1-(2-AMOXYPHENYL)-2-(METHYLTHIO)VINYL)IMIDAZOLE HYDROCHLORIDE
Systematic Name English
NETICONAZOLE HYDROCHLORIDE [MI]
Common Name English
Code System Code Type Description
SMS_ID
100000085735
Created by admin on Mon Mar 31 18:27:17 GMT 2025 , Edited by admin on Mon Mar 31 18:27:17 GMT 2025
PRIMARY
PUBCHEM
5282432
Created by admin on Mon Mar 31 18:27:17 GMT 2025 , Edited by admin on Mon Mar 31 18:27:17 GMT 2025
PRIMARY
FDA UNII
PKF582ZH6P
Created by admin on Mon Mar 31 18:27:17 GMT 2025 , Edited by admin on Mon Mar 31 18:27:17 GMT 2025
PRIMARY
CAS
130773-02-3
Created by admin on Mon Mar 31 18:27:17 GMT 2025 , Edited by admin on Mon Mar 31 18:27:17 GMT 2025
PRIMARY
EVMPD
SUB03414MIG
Created by admin on Mon Mar 31 18:27:17 GMT 2025 , Edited by admin on Mon Mar 31 18:27:17 GMT 2025
PRIMARY
ChEMBL
CHEMBL2107447
Created by admin on Mon Mar 31 18:27:17 GMT 2025 , Edited by admin on Mon Mar 31 18:27:17 GMT 2025
PRIMARY
MERCK INDEX
m7833
Created by admin on Mon Mar 31 18:27:17 GMT 2025 , Edited by admin on Mon Mar 31 18:27:17 GMT 2025
PRIMARY Merck Index
Related Record Type Details
Structure of NETICONAZOLE
PARENT -> SALT/SOLVATE
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966